Rhenman & Partners Asset Management Trims Neurocrine Biosciences Stake

The hedge fund reduced its holdings in the biopharmaceutical company by over 23% in Q3 2025.

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

Rhenman & Partners Asset Management AB, a hedge fund, trimmed its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 23.1% in the third quarter of 2025, according to the firm's latest 13F filing with the Securities and Exchange Commission. Rhenman & Partners Asset Management AB now owns approximately 114,717 shares of the biopharmaceutical company's stock, making it the 21st largest holding in their investment portfolio.

Why it matters

Neurocrine Biosciences is a prominent biopharmaceutical company focused on developing treatments for neurological, endocrine, and neuropsychiatric disorders. The reduction in Rhenman & Partners' stake could signal a shift in investor sentiment or portfolio rebalancing, which may impact the company's stock price and market position.

The details

In the third quarter, Rhenman & Partners Asset Management AB sold 34,500 shares of Neurocrine Biosciences, reducing its total holdings to 114,717 shares. This represents approximately 0.12% of the company's outstanding shares. Rhenman & Partners Asset Management AB cited the sale as part of its portfolio management strategy, but did not provide specific reasons for the reduction in its Neurocrine Biosciences position.

  • Rhenman & Partners Asset Management AB filed its 13F report for the third quarter of 2025 on March 8, 2026.

The players

Rhenman & Partners Asset Management AB

A hedge fund that manages investments in various sectors, including the biopharmaceutical industry.

Neurocrine Biosciences, Inc.

A biopharmaceutical company focused on developing treatments for neurological, endocrine, and neuropsychiatric disorders.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Rhenman & Partners' stake in Neurocrine Biosciences highlights the dynamic nature of the biopharmaceutical industry and the ongoing shifts in investor sentiment. While the specific reasons for the portfolio adjustment are not disclosed, it serves as a reminder for investors to closely monitor the activities of major institutional investors and the potential impact on the companies they hold.